The CDKN2A/CDKN2B/CDK4/CCND1 pathway is pivotal in well-differentiated and dedifferentiated liposarcoma oncogenesis. An analysis of 104 tumors

Genes Chromosomes and Cancer

Volumn 50, Issue 11, 2011, Pages 896-907

  Louis Brennetot, Caroline ^a   Coindre, Jean Michel ^b   Ferreira, Céline ^a   Pérot, Gaëlle ^a   Terrier, Philippe ^c   Aurias, Alain ^a  

^a INSTITUT CURIE   (France)

^b INSTITUT BERGONIÉ   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B;

AMPLICON; ARTICLE; CARCINOGENESIS; CELL CYCLE; CELL DIFFERENTIATION; CHROMOSOME 12; CHROMOSOME 1Q; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; LIPOSARCOMA; MAJOR CLINICAL STUDY; MALE; MUTATION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

BLOTTING, WESTERN; CELL DIFFERENTIATION; COMPARATIVE GENOMIC HYBRIDIZATION; CYCLIN D1; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE INHIBITOR P15; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENETIC LOCI; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LIPOSARCOMA; MALE; REAL-TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

EID: 80052663200     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20909     Document Type: Article

References (39)

1. Butti MG, Bongarzone I, Ferraresi G, Mondellini P, Borrello MG, Pierotti MA. 1995. A sequence analysis of the genomic regions involved in the rearrangements between TPM3 and NTRK1 genes producing TRK oncogenes in papillary thyroid carcinomas. Genomics 28: 15-24.
2. Cao X, Pfaff SL, Gage FH. 2008. YAP regulates neural progenitor cell number via the TEA domain transcription factor. Genes Dev 22: 3320-3334.
3. Coindre JM, Pedeutour F, Aurias A. 2010. Well-differentiated and dedifferentiated liposarcomas. Virchows Arch 456: 167-179.
4. Craig RW. 2002. MCL1 provides a window on the role of the BCL2 family in cell proliferation, differentiation and tumorigenesis. Leukemia 16: 444-454.
5. De Preter K, Speleman F, Combaret V, Lunec J, Laureys G, Eussen BH, Francotte N, Board J, Pearson AD, De Paepe A, Van Roy N, Vandesompele J. 2002. Quantification of MYCN, DDX1, and NAG gene copy number in neuroblastoma using a real-time quantitative PCR assay. Mod Pathol 15: 159-166.
6. Filipek A, Michowski W, Kuznicki J. 2008. Involvement of S100A6 (calcyclin) and its binding partners in intracellular signaling pathways. Adv Enzyme Regul 48: 225-239.
7. Fletcher CDM, Unni KK, Mertens F, editors. 2002. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone. Lyon: IARC Press. 427 p.
8. Frum R, Ramamoorthy M, Mohanraj L, Deb S, Deb SP. 2009. MDM2 controls the timely expression of cyclin A to regulate the cell cycle. Mol Cancer Res 7: 1253-1267.
9. Guled M, Lahti L, Lindholm PM, Salmenkivi K, Bagwan I, Nicholson AG, Knuutila S. 2009. CDKN2A, NF2, and JUN are dysregulated among other genes by miRNAs in malignant mesothelioma-A miRNA microarray analysis. Genes Chromosomes Cancer 48: 615-623.
10. Helias-Rodzewicz Z, Perot G, Chibon F, Ferreira C, Lagarde P, Terrier P, Coindre JM, Aurias A. 2010. YAP1 and VGLL3, encoding two cofactors of TEAD transcription factors, are amplified and overexpressed in a subset of soft tissue sarcomas. Genes Chromosomes Cancer 49: 1161-1171.
11. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. 1996. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93: 9821-9826.
12. Hostein I, Pelmus M, Aurias A, Pedeutour F, Mathoulin-Pelissier S, Coindre JM. 2004. Evaluation of MDM2 and CDK4 amplification by real-time PCR on paraffin wax-embedded material: a potential tool for the diagnosis of atypical lipomatous tumours/well-differentiated liposarcomas. J Pathol 202: 95-102.
13. Italiano A, Bianchini L, Keslair F, Bonnafous S, Cardot-Leccia N, Coindre JM, Dumollard JM, Hofman P, Leroux A, Mainguene C, Peyrottes I, Ranchere-Vince D, Terrier P, Tran A, Gual P, Pedeutour F. 2008. HMGA2 is the partner of MDM2 in well-differentiated and dedifferentiated liposarcomas whereas CDK4 belongs to a distinct inconsistent amplicon. Int J Cancer 122: 2233-2241.
14. Italiano A, Bianchini L, Gjernes E, Keslair F, Ranchere-Vince D, Dumollard JM, Haudebourg J, Leroux A, Mainguene C, Terrier P, Chibon F, Coindre JM, Pedeutour F. 2009. Clinical and biological significance of CDK4 amplification in well-differentiated and dedifferentiated liposarcomas. Clin Cancer Res 15: 5696-5703.
15. Jochum W, Passegue E, Wagner EF. 2001. AP-1 in mouse development and tumorigenesis. Oncogene 20: 2401-2412.
16. Kato J, Matsushime H, Hiebert SW, Ewen ME, Sherr CJ. 1993. Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes Dev 7: 331-342.
17. Kim WY, Sharpless NE. 2006. The regulation of INK4/ARF in cancer and aging. Cell 127: 265-275.
18. Krimpenfort P, Ijpenberg A, Song JY, van der Valk M, Nawijn M, Zevenhoven J, Berns A. 2007. p15Ink4b is a critical tumour suppressor in the absence of p16Ink4a. Nature 448: 943-946.
19. Lal A, Kim HH, Abdelmohsen K, Kuwano Y, Pullmann R, Jr., Srikantan S, Subrahmanyam R, Martindale JL, Yang X, Ahmed F, Navarro F, Dykxhoorn D, Lieberman J, Gorospe M. 2008. p16(INK4a) translation suppressed by miR-24. PLoS One 3: e1864.
20. Laud K, Marian C, Avril MF, Barrois M, Chompret A, Goldstein AM, Tucker MA, Clark PA, Peters G, Chaudru V, Demenais F, Spatz A, Smith MW, Lenoir GM, Bressac-de Paillerets B. 2006. Comprehensive analysis of CDKN2A (p16INK4A/p14ARF) and CDKN2B genes in 53 melanoma index cases considered to be at heightened risk of melanoma. J Med Genet 43: 39-47.
21. Mariani O, Brennetot C, Coindre JM, Gruel N, Ganem C, Delattre O, Stern MH, Aurias A. 2007. JUN oncogene amplification and overexpression block adipocytic differentiation in highly aggressive sarcomas. Cancer Cell 11: 361-374.
22. Mertens F, Johansson B, Hoglund M, Mitelman F. 1997. Chromosomal imbalance maps of malignant solid tumors: A cytogenetic survey of 3185 neoplasms. Cancer Res 57: 2765-2780.
23. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. 1992. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69: 1237-1245.
24. Morris M, Hepburn P, Wynford-Thomas D. 2002. Sequential extension of proliferative lifespan in human fibroblasts induced by over-expression of CDK4 or 6 and loss of p53 function. Oncogene 21: 4277-4288.
25. Nicolay BN, Frolov MV. 2008. Context-dependent requirement for dE2F during oncogenic proliferation. PLoS Genet 4: e1000205.
26. Ortega S, Malumbres M, Barbacid M. 2002. Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta 1602: 73-87.
27. Perot G, Derre J, Coindre JM, Tirode F, Lucchesi C, Mariani O, Gibault L, Guillou L, Terrier P, Aurias A. 2009. Strong smooth muscle differentiation is dependent on myocardin gene amplification in most human retroperitoneal leiomyosarcomas. Cancer Res 69: 2269-2278.
28. Perot G, Chibon F, Montero A, Lagarde P, de The H, Terrier P, Guillou L, Ranchere D, Coindre JM, Aurias A. 2010. Constant p53 pathway inactivation in a large series of soft tissue sarcomas with complex genetics. Am J Pathol 177: 2080-2090.
29. Rousseau-Merck MF, Fiette L, Klochendler-Yeivin A, Delattre O, Aurias A. 2005. Chromosome mechanisms and INI1 inactivation in human and mouse rhabdoid tumors. Cancer Genet Cytogenet 157: 127-133.
30. Salama I, Malone PS, Mihaimeed F, Jones JL. 2008. A review of the S100 proteins in cancer. Eur J Surg Oncol 34: 357-364.
31. Salomon-Nguyen F, Della-Valle V, Mauchauffe M, Busson-Le Coniat M, Ghysdael J, Berger R, Bernard OA. 2000. The t(1;12)(q21;p13) translocation of human acute myeloblastic leukemia results in a TEL-ARNT fusion. Proc Natl Acad Sci USA 97: 6757-6762.
32. Sandberg AA. 2004. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: Liposarcoma. Cancer Genet Cytogenet 155: 1-24.
33. Shen Q, Uray IP, Li Y, Krisko TI, Strecker TE, Kim HT, Brown PH. 2008. The AP-1 transcription factor regulates breast cancer cell growth via cyclins and E2F factors. Oncogene 27: 366-377.
34. Singer S, Socci ND, Ambrosini G, Sambol E, Decarolis P, Wu Y, O'Connor R, Maki R, Viale A, Sander C, Schwartz GK, Antonescu CR. 2007. Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma. Cancer Res 67: 6626-6636.
35. Szymanska J, Tarkkanen M, Wiklund T, Virolainen M, Blomqvist C, Asko-Seljavaara S, Tukiainen E, Elomaa I, Knuutila S. 1996. Gains and losses of DNA sequences in liposarcomas evaluated by comparative genomic hybridization. Genes Chromosomes Cancer 15: 89-94.
36. Szymanska J, Virolainen M, Tarkkanen M, Wiklund T, Asko-Seljavaara S, Tukiainen E, Elomaa I, Blomqvist C, Knuutila S. 1997. Overrepresentation of 1q21-23 and 12q13-21 in lipoma-like liposarcomas but not in benign lipomas: A comparative genomic hybridization study. Cancer Genet Cytogenet 99: 14-18.
37. Vincent-Salomon A, Gruel N, Lucchesi C, MacGrogan G, Dendale R, Sigal-Zafrani B, Longy M, Raynal V, Pierron G, de Mascarel I, Taris C, Stoppa-Lyonnet D, Pierga JY, Salmon R, Sastre-Garau X, Fourquet A, Delattre O, de Cremoux P, Aurias A. 2007. Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity. Breast Cancer Res 9: R24.
38. Wei G, Lonardo F, Ueda T, Kim T, Huvos AG, Healey JH, Ladanyi M. 1999. CDK4 gene amplification in osteosarcoma: Reciprocal relationship with INK4A gene alterations and mapping of 12q13 amplicons. Int J Cancer 80: 199-204.
39. Wolf M, Aaltonen LA, Szymanska J, Tarkkanen M, Elomaa I, Knuutila S. 1997. Microsatellite markers as tools for characterization of DNA amplifications evaluated by comparative genomic hybridization. Cancer Genet Cytogenet 93: 33-38.